The Drug Eluting Stents Center

Filter Your Results




Evaluating the Zilver PTX Stent

Michael D. Dake, MD; Gary M. Ansel, MD, FACC; and Anthony O. Ragheb, PHD

March 2010—Principal investigators discuss the clinical study design and initial results with the Zilver PTX drug-eluting peripheral stent in the SFA.

Cook Medical's Zilver PTX Stent Gains CE Mark to Treat SFA

August 11, 2009 -- Cook Medical (Bloomington, IN) announced that CE Mark approval has been granted for its Zilver PTX paclitaxel-eluting peripheral stent to treat severe b…

The Zilver PTX Global Registry and RCT

October 2008—Michael D. Dake, MD, discusses the early experiences in the Zilver PTX randomized trial and the results seen in the larger global registry studying a paclitaxel-eluting stent in the SFA.

Drug-Eluting Stents in the Periphery

H. Bob Smouse, MD

June 2007—A summary of the barriers, unanswered questions, and potential benefits of this technology.

Update: Drug-Eluting Stents in Tibial Arteries

Dierk Scheinert, MD

August 2007—Two-year results from the Leipzig Cypher BTK registry.

Biomechanical Forces in the Femoropopliteal Arterial Segment

H. Bob Smouse, MD; Alexander Nikanorov, MD, PhD; and Danielle LaFlash

June 2005—What happens during extremity movement and what is the effect on stenting?

The SIROCCO Studies

Matt Pesotski, Associate Editor

October 2003—The latest results from the SIROCCO studies—initial evaluations of drug-eluting stents in the SFA—show favorable outcomes.

Drug-Eluting Stents Target Restenosis


October 2002—An innovative technology continues to evolve.




Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.